RxDoctor Payments Data

Tina Thomas, MD

Nephrology · Houston, TXNPI 1659627248

Payments from drug & device makers

$2,056in general payments, 2019–2025

Across 117 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$680
  • AstraZeneca$382
  • Fresenius USA Marketing, Inc.$308
  • Amgen$76
  • Otsuka America Pharmaceutical, Inc.$75
  • OPKO Pharmaceuticals, LLC$64
  • plus $471 from 12 others

What the payments were for

  • Food & beverage$2,00097%
  • Education$553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,056 in reported general payments places this provider in the 50th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$191,822
Medicare patients
368
Services billed
2,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol44$39,250
VeltassaPatiromer Calcium Sorbitex12$15,747
LokelmaSodium Zirconium Cyclosilicate14$9,883
DapagliflozinDapagliflozin Propanediol13$6,546
Potassium Citrate ErPotassium Citrate28$3,197
Sevelamer Carbonate16$2,186
Febuxostat12$1,684
Nifedipine ErNifedipine38$1,567
Torsemide33$852
Amlodipine Besylate76$596
Doxazosin Mesylate24$594
Losartan Potassium73$490
Allopurinol65$481
Lisinopril54$453
Furosemide58$332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$382$49,13358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →